Building a world where
tomorrow is another day!

Home
サブ-ナビゲーション
  • Company
  • Science/Pipleline
  • News
  • Investor Relations
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

Home

News

  • Jun 29, 2026 Announcement of Publication of Research on the Discovery of CDK12 Inhibitor CTX-439 pdf (341KB)
  • Jun 15, 2026 Announcement of Dose-Escalation Cohort Data for Rogocekib Presented at the EHA Congress 2026 pdf (338KB)
  • May 19, 2026 Chordia Therapeutics Publishes First-in-Human Phase 1 Results of CLK Inhibitor Rogocekib for Solid Tumors in Clinical Cancer Research pdf (350KB)
  • May 13, 2026 Acceptance and Publication of Abstract on Dose-Escalation Cohort Data of rogocekib (CTX-712) at EHA 2026 pdf (270KB)

View All

Science

Science

Science

Development Pipeline

Development Pipeline

CLK Inhibitor CTX-712

CLK Inhibitor CTX-712

MALT1 Inhibitor CTX-177

MALT1 Inhibitor CTX-177

CDK12 Inhibitor CTX-439

CDK12 Inhibitor CTX-439

GCN2 Inhibitor CRD-1968099

GCN2 Inhibitor CRD-1968099

View All

Investor Relations
Investor Relations

Company

Corporate Name Chordia Therapeutics Inc.
Foundation November 1, 2017
Head Office 26-1, Muraoka-Higashi 2-chome,Fujisawa, Kanagawa 251-0012 Japan MAP
Tokyo Office 3-11-5,Nihonbashi-honcho,Chuo-ku,Tokyo 103-0023 Japan
Representative Hiroshi Miyake, Ph.D. CEO

Mission

Message

Leadership
Team

Career

Career

Career

Contact

Contact

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box